Molecule provides a platform for democratizing scientific research funding and tokenizing intellectual property, focusing on longevity research and innovative drug development. Self-described as a leader in the decentralized science movement, Molecule allows participation in funding and contributing to scientific projects.

Molecule AG

Molecule

Molecule AG | 4,264 followers on LinkedIn. A decentralised biotech protocol porting intellectual property into web3 and launching biotech DAOs | We propel science from lab to life, fueled by a community committed to human progress.

LongBio // Drug Hunter-Gatherer // CEO @ ImmuneAGE & GP @ Healthspan Capital

Sebastian A. Brunemeier

Web3 Biotech | Growth Marketer | Advancing Science for Human Impact

Jillian Casalini

Reimagining Intellectual Property

Chris Byrnes

Lead Product Designer at Molecule.to | Kernel Fellow KB7 🌱 | UX Researcher & Designer | Web3

María Sanmartín

Really interesting things happening in this space. Artan raised $300K through a governance token to fund experiments. The current valuation of the coin is around $11M. This is done through a decentralized science and transparent framework and the community has rights and privileges to guide the project. If you’re a researcher or company with an idea and $100K-$300K gets your somewhere meaningful, I suggest looking into this.

Michael Torres

We’re pleased to welcome Paul Kohlhaas , Founder & CEO of Molecule AG , as a speaker at #FtCBangkok ! 🧬 In his session, “DeSci Ecosystem Overview,” Paul will provide an in-depth look at the decentralized science (DeSci) ecosystem and discuss how DeSci is transforming the way we approach research, funding, and innovation. His insights will showcase the power of decentralization in reshaping the scientific landscape. 📅 November 8-9, 2024 👉 Register here: https://lnkd.in/dYCgFzhY

Funding the Commons

I recently attended Frontiers Health . It was a super interesting event; the first time I'd been to one of these bigger, more formal conferences. Moreover, it was particularly interesting because, in many ways, what we're building at Molecule AG aims to completely disrupt the work most of these people do day-to-day. Despite this, those same people light up when you get to the meat of what we're trying to accomplish. All of them remain certain technology is the tool for progress, and web3 is another layer to that (and one that I believe is inevitable!). Some honorable mentions: Click Therapeutics, Inc. who is building software as prescription medicine dacadoo on digital health solutions Inceptive creating tools for biological software Thanks to Nana Bit-Avragim (she/her) for the invite. Also shoutout to Logan Bishop-Currey for being the best conf buddy and killing it on stage. Kk, that's all from me!

Ella McCarthy-Page

Excited to host our Nucleate friends next month!

🚀 Get Ready for the 𝗔𝗰𝘁𝗶𝘃𝗮𝘁𝗼𝗿 𝗞𝗶𝗰𝗸𝗼𝗳𝗳 in Berlin! 🚀 We're thrilled to 𝗹𝗮𝘂𝗻𝗰𝗵 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗔𝗰𝘁𝗶𝘃𝗮𝘁𝗼𝗿 𝘀𝗲𝗮𝘀𝗼𝗻 with an evening dedicated to connecting Berlin’s biotech community 🧬 🔬 This kickoff event is your chance to 𝗵𝗲𝗮𝗿 𝗳𝗿𝗼𝗺 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗲𝘅𝗽𝗲𝗿𝘁𝘀, 𝗹𝗲𝗮𝗿𝗻 𝗳𝗿𝗼𝗺 𝗽𝗮𝘀𝘁 𝗔𝗰𝘁𝗶𝘃𝗮𝘁𝗼𝗿 𝘁𝗲𝗮𝗺𝘀, and engage in thought-provoking 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻𝘀. What to expect: 🔴 𝗧𝗮𝗹𝗸𝘀 & 𝗣𝗮𝗻𝗲𝗹 – Gain insights from leaders in biotech and previous Activator teams (more info on speakers, programming and schedule to come!) 🔴 𝗡𝗲𝘁𝘄𝗼𝗿𝗸𝗶𝗻𝗴 – Enjoy food and drinks while meeting scientists, founders, investors, industry leaders, and others who share a passion for biotech innovation. Thanks to our sponsor Molecule AG for providing us an amazing event location. Secure your spot now and become part of our growing biotech community! 📍 Where: 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲, 𝗔𝗹𝗲𝘅𝗮𝗻𝗱𝗿𝗶𝗻𝗲𝗻𝘀𝘁𝗿𝗮𝘀𝘀𝗲 𝟭𝟭𝟴-𝟭𝟮𝟭, 𝗕𝗲𝗿𝗹𝗶𝗻 🕐 When: 17:00 📅 Register Now: https://lu.ma/8cm1kwak Don’t miss the chance to launch your venture with us! #NucleateGermany #LifeScienceStartups #BioEntrepreneurship #ActivatorProgram #StartupKickoff #BerlinEvents #BioTech #EcoInnovation #Therapeutics #Diagnostics #SustainableStartups #CleanEnergy #StartupGermany #InnovationCommunity #LifeScienceInnovation

Nucleate Germany

We talk a lot about accelerating science in DeSci. But what does this actually look like? DeSci's impact on initial funding for drug discovery is clear, but there is another crucial step in bringing a drug to market: Preclinical Studies. And it's with preclinical studies that DeSci can set a new standard. 🔬 Traditional drug development often takes over a decade, with a lot of effort focused on clinical trials. But we can dramatically speed up the preclinical stage, making it more efficient and sustainable, with DeSci. The current state of preclinical studies: 🔹 Identifying & Validating Targets 🔹 Optimizing Lead Compounds 🔹 Testing Safety & Toxicity 🔹 Studying Pharmacokinetics These crucial steps lay the foundation for drug development, and there is a lot of room for improvement. DeSci is disrupting and accelerating preclinical research by: 🔹 Directing resources to high-impact research 🔹 Making decisions transparent with IP-NFT & IPT governance 🔹 Enhancing collaboration by sharing data 🔹 Accelerating target identification 🔹 Improving reproducibility This transformation brings unprecedented opportunities: For Researchers 🔬 - Unlocks access to funding - Provides faster testing pathways - Reduces early-stage research delays For Institutions 🏛️ - Acts as a risk-mitigation tool for pharma - Offers transparent, capital-efficient funding models - Supports and sustains innovative research For Funders 🤝 - Democratizes access to scientific research - Enables anyone to fund and participate in world-changing research through IPTs DeSci doesn't just improve drug discovery—it transforms it. By building tools to optimize preclinical studies, we're tackling one of the biggest bottlenecks in R&D. Our aim? To bring new treatments to patients faster than ever through collaboration and efficient systems. The future of drug discovery is decentralized, transparent, and lightning-fast. Are you ready to be part of this revolution?

Zelar City comes at Molecule AG DeSci Church! This Sat and Sun we discuss Decentralized Science and Network states! Join us! https://lu.ma/4spe1nm5 Victoria Forest , Laurence Ion , Elias Schlie 🚀🚀🚀

Alexey Strygin

#DeSci and #NetworkStates Summit Day 1 at DeSci Church with Molecule AG This place is the perfect blend of art and science. The conversations are thought-provoking, and people are curious and open to changing the status quo 🔥 Zelar City has reached its halfway mark! Don’t miss the 3 remaining weekend summits. Check out the weekly themes at https://zelar.city

Victoria Forest

Over this weekend, there were two amazing Zelar City summits on Decentralized Science (DeSci) and Network States in #longevity 🖥️💉 The talks and workshops of the speakers as well as presented ideas and projects on the impact of decentralized science on rapid research development in medicine were extremely insighful! The implications of novel regulations in healthcare, the emergence of pop-up cities (maybe even countries? Liberland ), and the creation of global networks that further collaboration between researchers across the globe—all of these aspirations can help us advance life sciences and foster longevity among a larger public. Thank you so much, Victoria Forest , Laurence Ion , Alexey Strygin , and Elias Schlie , Mark Kagach for being such a fascinating team with whom it is such a pleasure to work 🙌 Also, huge thanks to the whole Molecule AG team for welcoming Zelar City to spread the knowledge about the potential behind #DeSci ! Zelar City will continue gathering longevity enthusiasts from all across the world in Berlin for the next 3 weeks! Our next summit will be about Health Optimization and AI: https://lu.ma/omxsp5xu Come and join us in our mission to extend human lifespan!

Elena Mishina

There's a lot of excitement in crypto around Real-World Assets (RWAs). However, unlike loans and bonds, IP is the ultimate meta-RWA—an asset perfect for tokenization. What are IPTs? Intellectual Property Tokens (IPTs) are fungible governance tokens of an IP-NFT (a tokenized representation of IP). They're transforming how research IP is managed, governed, and monetized—enabling open-source collaboration without losing commercial opportunity. Onchain science is already underway & making incredible strides. And VitaDAO is leading the charge with two remarkable projects combating age-related diseases: VitaFAST: The first-ever IPT funding longevity science 🧪 VitaFAST enables governance of the Viktor Korolchuk Lab IP-NFT, a project focused on discovering novel autophagy enhancers (think "fasting!"). Last year, the VitaDAO community raised over $300,000 to continue the lab's research! VitaRNA: Groundbreaking Gene Therapy 🧬 VitaRNA tokenizes the ARTAN Bio IP-NFT—exploring the promising field of gene therapies that could help address aging-related genetic factors. The VitaDAO community also raised $300,000 to continue Artan Bio's research into their AAV9-based gene therapy. What do IPTs mean for scientific innovation? 🧪 IPTs help accelerate research by aligning incentives around a community of stakeholders that have an opportunity to govern IP and contribute to the research itself. IPTs are the future of scientific innovation, and VitaFAST & VitaRNA are proving just how powerful onchain science is ⛓️🔬 Ready to get involved? 🤝 Connect with the teams: VitaFAST: vitafast.xyz VitaRNA: vitarna.xyz

MOLE

XYZ:MOLECULE

Molecule

locale

market

industry

website

linkedin

competitor of

Metrics